‘New hope for advanced prostate cancer patients’

GenesisCare has recently worked with Health Awareness UK and the Guardian on their Urology Health campaign. Read our article that appeared in the Guardian on Monday 23rd September 2019 where Yong Du, Clinical Director, Nuclear Medicine and Theranostics talks about how 177Lutetium PSMA therapy works and it’s benefits to men with late stage prostate cancer and Hans-Jurg Schaupp’s experience of this revolutionary therapy. Hans received his therapy at GenesisCare in Windsor and was the first patient in the UK to receive 177Lutetium PSMA therapy.

Read the full article here.

Related articles

Honouring Clinical Excellence & Leadership: GenesisCare Launches Inaugural Global Physician Recognition Program

GenesisCare Appoints Seven Leading Oncologists to Chair its Global Research Committees

SABR Consortium Annual Professional Conference 2021

Annual research report 2020